Intravitreal injections are extensively used to treat various retinal diseases, and bevacizumab, a humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody is a common therapeutic agent for exudative age-related macular degeneration and macular edema resulting from diabetic retinopathy or retinal vein occlusion (RVO). This evidence concerns the gene VEGFA and Abnormal retinal morphology.